4.6 Article

Molecular heterogeneity in human papillomavirus-dependent and -independent vulvar carcinogenesis

Journal

CANCER MEDICINE
Volume 7, Issue 9, Pages 4542-4553

Publisher

WILEY
DOI: 10.1002/cam4.1633

Keywords

copy number alterations; human papillomavirus; progression risk; vulvar intraepithelial neoplasia; vulvar squamous cell carcinoma

Categories

Funding

  1. GSK
  2. Qiagen
  3. SPMSD/Merck
  4. Roche diagnostics
  5. Menarini
  6. Seegene

Ask authors/readers for more resources

Vulvar squamous cell carcinoma (VSCC) and precancerous vulvar intraepithelial neoplasia (VIN) can develop through human papillomavirus (HPV)-dependent and -independent pathways, indicating a heterogeneous disease. Only a minority of VIN progress, but current clinicopathological classifications are insufficient to predict the cancer risk. Here we analyzed copy number alterations (CNA) to assess the molecular heterogeneity of vulvar lesions in relation to HPV and cancer risk. HPV-status and CNA by means of whole-genome next-generation shallow-sequencing were assessed in VSCC and VIN. The latter included VIN of women with associated VSCC (VINVSCC) and women who did not develop VSCC during follow-up (VINnoVSCC). HPV-testing resulted in 41 HPV-positive (16 VINVSCC, 14 VINnoVSCC, and 11 VSCC) and 24 HPV-negative (11 VINVSCC and 13 VSCC) lesions. HPV-positive and -negative VSCC showed a partially overlapping pattern of recurrent CNA, including frequent gains of 3q and 8q. In contrast, amplification of 11q13/cyclinD1 was exclusively found in HPV-negative lesions. HPV-negative VINVSCC had less CNA than HPV-negative VSCC (P = .009), but shared chromosome 8 alterations. HPV-positive VINnoVSCC had less CNA than VIN vscc (P = .022). Interestingly, 1pq gain was detected in 81% of HPV-positive VINVSCC and only in 21% of VINnoVSCC (P = .001). In conclusion, HPV-dependent and -independent vulvar carcinogenesis is characterized by distinct CNA patterns at the VIN stage, while more comparable patterns are present at the cancer stage. Cancer risk in VIN seems to be reflected by the extent of CNA, in particular chromosome 1 gain in HPV-positive cases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Oncology

Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses

Jan M. Van Rees, Lissa Wullaert, Alexander A. J. Grueter, Yassmina Derraze, Pieter J. Tanis, Henk M. W. Verheul, John W. M. Martens, Saskia M. Wilting, Geraldine Vink, Jeroen L. A. Van Vugt, Nick Beije, Cornelis Verhoef

Summary: This systematic review and meta-analyses demonstrate a strong association between ctDNA and recurrent disease in non-metastatic rectal cancer. ctDNA analysis can stratify patients into high and low risk groups for recurrence, especially when detected after neoadjuvant treatment and surgery. Future research should focus on the feasibility of ctDNA-guided treatment and follow-up strategies in rectal cancer.

FRONTIERS IN ONCOLOGY (2023)

Article Oncology

Clinical validation of methylation biomarkers for optimal detection of high-grade vulvar intraepithelial neoplasia

Feline O. Voss, Nikki B. Thuijs, Sylvia Duin, Mujde Ozer, Marc van Beurden, Johannes Berkhof, Renske D. M. Steenbergen, Maaike C. G. Bleeker

Summary: This study aimed to validate the accuracy of previously identified DNA methylation markers for detection of high-grade vulvar intraepithelial neoplasia (VIN). The best-performing individual marker was found to be SST, detecting 80% of high-grade VIN cases, with excellent detection of HPV-independent VIN, known to have the highest cancer risk. Selection of a marker panel including ZNF582, SST, and miR124-2 also yielded high accuracy for detection of high-grade VIN.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Oncology

mFast-SeqS-based aneuploidy score in circulating cell-free DNA is a prognostic biomarker in prostate cancer

Khrystany T. Isebia, Bianca Mostert, Teoman Deger, Jaco Kraan, Vanja de Weerd, Esther Oomen-de Hoop, Paul Hamberg, Brigitte C. M. Haberkorn, Helgi H. Helgason, Ronald de Wit, Ron H. J. Mathijssen, Martijn P. Lolkema, Saskia M. Wilting, Job van Riet, John W. M. Martens

Summary: In this study, the researchers found that the abnormal aneuploidy score of cell-free tumor DNA (ctDNA) in the blood can predict the survival of metastatic castration-resistant prostate cancer (mCRPC) patients, making it a potential biomarker.

MOLECULAR ONCOLOGY (2023)

Article Oncology

Methylated Cell-Free DNA Sequencing (MeD-seq) of LpnPI Digested Fragments to Identify Early Progression in Metastatic Renal Cell Carcinoma Patients on Watchful Waiting

Manouk K. Bos, Sarah R. Verhoeff, Sjoukje F. Oosting, Willemien C. van der Houven van Oordt, Ruben G. Boers, Joachim B. Boers, Joost Gribnau, John W. M. Martens, Stefan Sleijfer, Carla M. L. van Herpen, Saskia M. Wilting

Summary: For patients with intermediate risk renal cell carcinoma, some have a slow disease progression. Delaying treatment for metastatic disease by entering a watchful waiting period is a safe option for these patients. However, it is currently difficult to identify patients with indolent disease or those with rapidly progressive disease. This study investigates the use of cell-free DNA (cfDNA) as a blood-based biomarker to identify patients with rapid disease progression.

CANCERS (2023)

Article Oncology

Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients? Needs?

Elisabeth M. Jongbloed, Hedwig M. Blommestein, Hannah M. van Schoubroeck, John W. M. Martens, Saskia M. Wilting, Carin A. Uyl-de Groot, Agnes Jager

Summary: The addition of two years of abemaciclib treatment to high-risk ER+, HER2-early breast cancer patients has been approved by the FDA. Using detection of minimal residual disease (MRD) through patient-informed circulating tumor DNA assays, the addition of abemaciclib treatment shows cost-effectiveness for high-risk patients. However, adding abemaciclib to all high-risk patients is not cost-effective, while MRD-guided treatment is more cost-effective compared to standard treatment.

BREAST CANCER-TARGETS AND THERAPY (2023)

Article Cell Biology

High-grade vulvar intraepithelial neoplasia: comprehensive characterization and long-term vulvar carcinoma risk

Nikki B. Thuijs, Marc van Beurden, Sylvia Duin, Danielle A. M. Heideman, Johannes Berkhof, Renske D. M. Steenbergen, Maaike C. G. Bleeker

Summary: This study comprehensively classified and assessed a large series of vulvar lesions, finding that 88.4% of high-grade VIN were associated with HPV and 10.9% were HPV independent. Immunohistochemistry testing for p16INK4a and p53 is important for distinguishing between the two types, which have different cancer risks.

HISTOPATHOLOGY (2023)

Article Multidisciplinary Sciences

Machine learning-based somatic variant calling in cell-free DNA of metastatic breast cancer patients using large NGS panels

Elisabeth M. Jongbloed, Maurice P. H. M. Jansen, Vanja de Weerd, Jean A. Helmijr, Corine M. Beaufort, Marcel J. T. Reinders, Ronald van Marion, Wilfred F. J. van IJcken, Gabe S. Sonke, Inge R. Konings, Agnes Jager, John W. M. Martens, Saskia M. Wilting, Stavros Makrodimitris

Summary: Next generation sequencing of cfDNA is a promising method for treatment monitoring and therapy selection in MBC. However, distinguishing tumor-specific variants from sequencing artefacts and germline variation is challenging. To address this, a machine learning model was built to remove false positive variant calls and select tumor-derived variants.

SCIENTIFIC REPORTS (2023)

Article Oncology

Hypermethylation of DNA Methylation Markers in Non-Cirrhotic Hepatocellular Carcinoma

Siyu Fu, Teoman Deger, Ruben G. Boers, Joachim B. Boers, Michael Doukas, Joost Gribnau, Saskia M. Wilting, Jose D. Debes, Andre Boonstra

Summary: In this study, aberrant hypermethylation changes in HOXA1, CLEC11A, AK055957, and TSPYL5 were identified in non-cirrhotic HCC tissues compared to cirrhosis, hepatitis, and benign lesions, providing potential detectable biomarkers for these unusual HCC cases.

CANCERS (2023)

Article Oncology

Liquid Biopsies for Colorectal Cancer and Advanced Adenoma Screening and Surveillance: What to Measure?

Ellis L. Eikenboom, Saskia M. Wilting, Teoman Deger, Malgorzata I. Srebniak, Monique Van Veghel-Plandsoen, Ruben G. Boers, Joachim B. Boers, Wilfred F. J. van IJcken, Joost H. Gribnau, Peggy Atmodimedjo, Hendrikus J. Dubbink, John W. M. Martens, Manon C. W. Spaander, Anja Wagner

Summary: We assessed which ctDNA assay might be most suitable for a ctDNA-based CRC screening/surveillance blood test. The results showed that cfDNA methylation profiles could discriminate all microsatellite instable advanced neoplasia, making it a particularly promising tool for Lynch syndrome surveillance. Larger studies are needed to validate these findings.

CANCERS (2023)

Article Oncology

Genomic Alterations Associated with Estrogen Receptor Pathway Activity in Metastatic Breast Cancer Have a Differential Impact on Downstream ER Signaling

Lindsay Angus, Marcel Smid, Saskia M. Wilting, Manouk K. Bos, Neeltje Steeghs, Inge R. H. M. Konings, Vivianne C. G. Tjan-Heijnen, Johanna M. G. H. van Riel, Agnes J. van de Wouw, Edwin Cuppen, Martijn P. Lolkema, Agnes Jager, Stefan Sleijfer, John W. M. Martens

Summary: This study investigated the mutated genes and mutation patterns, as well as the expression levels of relevant genes, in 101 breast cancer metastatic lesions with ER-positive tumors. The analyses revealed two distinct patient groups, one showing ongoing, active ER and its associated signal route, and the other showing lower ER expression levels. The study highlights the importance of combining mutation and expression analyses to identify patients who may still benefit from anti-hormonal treatment targeting ER.

CANCERS (2023)

Review Cell Biology

Circulating Tumour DNA as Biomarker for Colorectal Liver Metastases: A Systematic Review and Meta-Analysis

Lissa Wullaert, Jan M. van Rees, John W. M. Martens, Henk M. W. Verheul, Dirk J. Grunhagen, Saskia M. Wilting, Cornelis Verhoef

Summary: This study provides an overview and meta-analysis of the current literature on the value of ctDNA in patients with colorectal liver metastases. The results show a strong association between detectable ctDNA after surgery or completion of adjuvant therapy and oncological outcomes. However, there is no association between detectable ctDNA before surgery and oncological outcomes.

CELLS (2023)

Article Oncology

Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival

Noortje Verschoor, Vanja de Weerd, Mai N. Van, Jaco Kraan, Marcel Smid, Joan B. Heijns, Jan C. Drooger, Johanna M. Zuetenhorst, Annemieke van der Padt-pruijsten, Agnes Jager, Stefan Sleijfer, John W. M. Martens, Saskia M. Wilting

Summary: This study demonstrates that mFAST-SeqS can serve as a strong prognostic marker for MBC patients. It is an affordable and easily implementable method for assessing ctDNA levels, offering an alternative tool for prognosis. The aneuploidy score obtained using mFAST-SeqS is significantly correlated with CTC count and is a significant prognostic marker for both PFS and OS in MBC patients.

NPJ BREAST CANCER (2023)

Article Oncology

The risk of lymph node metastasis in the new FIGO 2018 stage IA cervical cancer with >7 mm diameter

Laure Nicolai, Refika Yigit, Maaike C. G. Bleeker, Joost Bart, Jacobus van der Velden, Constantijne H. Mom

Summary: For patients with stage IA cervical cancer with a diameter >7 mm, we recommend considering a pelvic lymph node assessment in case of DOI >3 mm and/or presence of LVSI.

JOURNAL OF GYNECOLOGIC ONCOLOGY (2023)

Article Oncology

Can we use a simple blood test to reduce unnecessary adverse effects from radiotherapy by timely identification of radiotherapy-resistant rectal cancers? MeD-Seq rectal study protocol

D. M. Mens, J. M. van Rees, S. M. Wilting, C. Verhoef

Summary: Chemoradiation therapy (CRT) is the standard of care for treating rectal cancer, but it can cause damage to the surrounding healthy tissue and not all patients benefit from it. This study aims to develop a diagnostic innovation using DNA methylation to predict the effectiveness of CRT for rectal cancer patients.

BMC CANCER (2023)

Article Oncology

Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer

Noortje Verschoor, Marcel Smid, Agnes Jager, Stefan Sleijfer, Saskia M. Wilting, John W. M. Martens

Summary: In this study, the researchers investigated the characteristics and therapy resistance of HER2-positive breast cancer through integrating genomics and transcriptomics data. They found that the genomic profiles of primary and metastatic HER2-positive breast cancers were similar, and certain genomic features were predictive of progression-free survival on post-biopsy anti-HER2 treatment. Additionally, a HER2-driven expression profile grouped different types of HER2-positive tumors and indicated the possibility of transformation to ER independence. Integrated genomic and transcriptomic analyses may play a key role in establishing therapeutic options.

BREAST CANCER RESEARCH (2023)

No Data Available